Citations

Clear

116 citation(s) found for "Davis, Mark".

Histopathologic Features in Vancomycin‐Associated Drug‐Induced Hypersensitivity Syndrome
Haberecht, Hannah, Ziebart, Rachel, Iverson, Olivia , Todd, Austin, Davis, Mark D. P. , Wetter, David A. , Sartori‐Valinotti, Julio C. , McEvoy, Marian T., Aghazadeh, Nessa , Johnson, Emma F. , Haberecht, Hannah B , Ziebart, Rachel L, Iverson, Olivia C, Davis, Mark D., Cantwell, Hafsa M. , Aghazadeh Mohandesi, Nessa , Ziebart, Rachel L , Davis, Mark D.P. , Alavi, Afsáneh

Mayo Clinic

Journal of Cutaneous Pathology | March 25, 2025 | Volume: 52 | Issue: 6 | Pages: 442-451

10.1111/cup.14804 | PMID 40129304 Get It

ABSTRACTBackgroundDrug‐induced hypersensitivity syndrome (DiHS), or drug reaction with eosinophilia and systemic symptoms (DRESS), is a delayed and severe immune response to certain medications. We investigated vancomycin‐induced DiHS/DRESS, notable for frequent and severe organ involvement, to describe its specific histopathology and the correlations between histopathologic and clinical findings.MethodsA retrospective review was conducted to identify patients between 2006 and 2022 who received vancomycin, had archived skin biopsy specimens, and were scored as having probable or definite DiHS/DRESS. Clinical features were retrospectively collected, and biopsy specimens were reviewed by a board‐certified dermatopathologist. A subset of histopathologic and clinical features was analyzed for statistical correlation.ResultsTwenty‐three patients met the inclusion criteria. Most biopsy specimens (87%) showed an eczematous reaction pattern; 17 (74%) showed a secondary reaction pattern. Spongiosis (87%) and neutrophilic infiltration (91%) were common epidermal characteristics. The dermal inflammatory infiltrate was frequently superficial (87%) and consistently included plasma cells (96%). Eosinophils were present in the dermis in 70% of cases. Parakeratosis negatively correlated with liver involvement and positively correlated with desquamative rash. Epidermal lymphocytes were negatively correlated with the RegiSCAR score.ConclusionsVancomycin‐associated DiHS/DRESS histopathology was characterized by a frequent eczematous reaction pattern, multiple coexisting reaction patterns, and epidermal neutrophilic infiltration.
Patch Testing in Solid Organ Transplant Recipients: Experience from a Tertiary Medical Center over 13 Years (2010–2022)
Wang, Katherine , Tolaymat, Leila , Davis, Mark D. P. , Youssef, Molly J. , Yiannias, James A. , Yang, Yul W. , Hall, Matthew R. , Wang, Katherine L , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | December 9, 2024 | Volume: 36 | Issue: 3 | Pages: 216-220

10.1089/derm.2024.0331 | PMID 39653361 Get It

Abstract: Background: It is generally recommended that patients not be on immunosuppressive medications for patch testing, as these medications may suppress delayed-type hypersensitivity and lead to false negative results. There is a paucity of literature describing organ transplant recipients who underwent patch testing. Objective: The aim of this study is to examine patch testing results in solid organ transplant recipients over a 13-year period at our institution. Methods: We performed a retrospective analysis of patch test data from adult transplant recipients at our institution. Transplant patients who underwent patch testing were identified from a clinical patch test database, and a chart review was conducted. Results: Eighteen patients were included in the study. Patients had received kidney, liver, or heart transplants. Seven patients (38.9%) had at least one positive reaction. The highest reaction rates were seen with methylisothiazolinone (12.5%), methyldibromo glutaronitrile (12.5%), and benzalkonium chloride (10.0%). Limitations included small sample size, data from a tertiary referral center, and retrospective analysis. Conclusions: Liver and kidney transplant recipients displayed allergic reactions during patch testing. Patients may benefit from patch testing even if receiving immunosuppressive therapy, but some reactions may be falsely negative because of immunosuppression.
Secukinumab in bio‐experienced patients with moderate‐to‐severe hidradenitis suppurativa from a single center: an observational retrospective study
Tran, Thuy M., Tran, Thuy M., Akpala, Christeebella O. , Tran, Tung S. , Davis, Mark , Baum, Christian L. , Wetter, David A., Nguyen, Giang Huong , Akpala, Christeebella O , Tran, Tung S , Davis, Mark Denis P., Nguyen, Giang H , Tran, Thuy M., Tran, Thuy M., Davis, Mark Denis P., Alavi, Afsáneh , Wetter, David A.

Mayo Clinic

International Journal of Dermatology | November 20, 2024 | Volume: 64 | Issue: 5 | Pages: 949-951

10.1111/ijd.17583 | PMID 39564701 Get It

Vascular Disease Patient Information Page: Erythromelalgia
Ratchford, Elizabeth V , Solomon, Alexandra , Davis, Mark D. P. , Solomon, Alexandra L , Davis, Mark DP., Davis, Mark D.P.

Mayo Clinic

Vascular Medicine | October 9, 2024 | Volume: 29 | Issue: 6 | Pages: 735-738

10.1177/1358863x241285533 | PMID 39380163 Get It

Procedural interventions for erythromelalgia: A narrative review
Lee, Jinnee U.J. , Janice, E., Sartori‐Valinotti, Julio C. , Rooke, Thom W. , Sandroni, Paola , Watson, James C. , Davis, Mark D. P. , Lee, Jinnee Uj , Davis, Mark DP., Davis, Mark D.P.

Mayo Clinic

Vascular Medicine | September 26, 2024 | Volume: 29 | Issue: 6 | Pages: 723-732

10.1177/1358863x241279427 | PMID 39319570 Get It

Erythromelalgia is a rare disorder characterized by episodic burning pain with redness and warmth of the extremities. Topical and systemic medications are the mainstay of management. We reviewed the published evidence for using procedural interventions to manage erythromelalgia, including their proposed mechanism of action and possible adverse effects, and included information in this review on epidural infusion, sympathetic ganglion block, sympathectomy, pulsed radiofrequency, spinal cord stimulation, dorsal root ganglion stimulation, brain stimulation, transcranial magnetic stimulation, and botulinum toxin injections. Both successful and unsuccessful outcomes have been reported. Although these procedural interventions extend the therapeutic options for erythromelalgia, the evidence for their use is limited. Case reports and small case series comprise most of the evidence. Based on our review, a multidisciplinary approach to management may be needed for patients with erythromelalgia.
Myelodysplasia cutis and VEXAS syndrome initially diagnosed as histiocytoid Sweet syndrome: A diagnostic pitfall
Shimshak, Serena , Jasmine, Sion W., Davis, Mark D.P. , Johnson, Emma F. , Peters, Margot S. , Zheng, Gang , Sokumbi, Olayemi , Comfere, Nneka I. , Shimshak, Serena J E , Jasmine, Sion, Sokumbi, Olayemi

Mayo Clinic

Journal of Cutaneous Pathology | July 12, 2024 | Volume: 51 | Issue: 11 | Pages: 834-839

10.1111/cup.14678 | PMID 38993097 Get It

AbstractHistiocytoid Sweet syndrome (H‐SS) is a histopathological variant of Sweet syndrome (SS) defined by cutaneous infiltration of immature myeloid cells morphologically resembling histiocytes. The association of H‐SS with underlying malignancy, particularly myelodysplastic syndromes, is well‐established. Myelodysplasia cutis (MDS‐cutis) has been proposed to describe cases historically diagnosed as H‐SS but characterized by shared clonality of the myeloid infiltrate in skin and bone marrow. Therefore, identifying patients who might have MDS‐cutis is critical for the management of the associated hematologic malignancy. VEXAS syndrome, an adult‐onset autoinflammatory disease, should also be included in the histopathologic differential diagnosis of H‐SS, as it shares clinical and pathologic features with MDS‐cutis. Through the presentation of two cases, we aim to highlight the defining features and key clinical implications of MDS‐cutis and VEXAS syndrome.
HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease
Yogeshwar, Selina , Muñiz‐Castrillo, Sergio , Sabater, Lídia , Peris-Sempere, Vicente, Mallajosyula, Vamsee , Guo, Luo, Yan, Han , Lin, Ling , Bueno, Flavia Fagundes, Ji, Xuhuai , Picard, Géraldine , Pinto, Anne Laurie, Heidbreder, Anna , Dalmau, Josep , Santamaría, Joan , Iranzo, Alex, Schreiner, Bettina , Giannoccaro, Maria Pia , Kimura, Akio , Ono, Yoya , Bonello, Michael , Nigro, Pasquale , Prüß, Harald , McKeon, Andrew, Irani, Sarosh R. , Gaig, Carles , Mignot, Emmanuel , Luo, Guo , Yogeshwar, Selina M , Höftberger, Romana , Iranzo, Alex , Dinoto, Alessandro , Irani, Sarosh R , Honnorat, Jérôme , Finke, Carsten , Mignot, Emmanuel , Muñiz-Castrillo, Sergio , Dalmau, Josep O , Heidbreder, Anna , Luo, Guo, Yu, Eric , Zhang, Jing , Rogemond, Véronique , Graus, Francesc , Liguori, Rocco , Shimohata, Takayoshi , Binks, Sophie , Mariotto, Sara , Dinoto, Alessandro , Hartmann, Christian Johannes , Tambasco, Nicola , McKeon, Andrew , Davis, Mark M. , Honnorat, Jérôme

Mayo Clinic

Brain | March 1, 2024 | Volume: 147 | Issue: 7 | Pages: 2579-2592

10.1093/brain/awae048 | PMID 38425314 Get It

Abstract Anti-IgLON5 disease is a rare and likely underdiagnosed subtype of autoimmune encephalitis. The disease displays a heterogeneous phenotype that includes sleep, movement and bulbar-associated dysfunction. The presence of IgLON5-antibodies in CSF/serum, together with a strong association with HLA-DRB1*10:01∼DQB1*05:01, supports an autoimmune basis. In this study, a multicentric human leukocyte antigen (HLA) study of 87 anti-IgLON5 patients revealed a stronger association with HLA-DQ than HLA-DR. Specifically, we identified a predisposing rank-wise association with HLA-DQA1*01:05∼DQB1*05:01, HLA-DQA1*01:01∼DQB1*05:01 and HLA-DQA1*01:04∼DQB1*05:03 in 85% of patients. HLA sequences and binding cores for these three DQ heterodimers were similar, unlike those of linked DRB1 alleles, supporting a causal link to HLA-DQ. This association was further reflected in an increasingly later age of onset across each genotype group, with a delay of up to 11 years, while HLA-DQ-dosage dependent effects were also suggested by reduced risk in the presence of non-predisposing DQ1 alleles. The functional relevance of the observed HLA-DQ molecules was studied with competition binding assays. These proof-of-concept experiments revealed preferential binding of IgLON5 in a post-translationally modified, but not native, state to all three risk-associated HLA-DQ receptors. Further, a deamidated peptide from the Ig2-domain of IgLON5 activated T cells in two patients, compared with one control carrying HLA-DQA1*01:05∼DQB1*05:01. Taken together, these data support a HLA-DQ-mediated T-cell response to IgLON5 as a potentially key step in the initiation of autoimmunity in this disease.
Pediatric Patch Testing at Mayo Clinic between 2016 and 2020
Wang, Katherine , Rainosek, Erin , Yang, Yul W. , Drage, Lisa A., Yiannias, James A. , Davis, Mark D. P. , Hall, Matthew R. , Youssef, Molly J. , Wang, Katherine L , Rainosek, Erin M, Cantwell, Hafsa M. , Hall, Matthew R , Davis, Mark D.P.

Mayo Clinic

Dermatitis® | February 6, 2024 | Volume: 35 | Issue: 4 | Pages: 355-360

10.1089/derm.2023.0353 | PMID 38320242 Get It

Abstract: Background: Allergic contact Dermatitis (ACD) is a common condition within the pediatric population. Patch testing is an important way to identify relevant allergens. Objective: To provide an update of the common contact allergens seen in children based on patch testing data at our institution from 2016 to 2020. Methods: We performed a retrospective analysis of patch test data from children aged 1–18 years from 2016 to 2020 at Mayo Clinic. Reaction rates were compared to the rates reported by the Pediatric Contact Dermatitis Registry (PCDR). Results: One hundred ninety-two children aged 1–18 were patch tested to various allergens. A total of 15,457 allergens were tested, with 291 positive tests. The top 5 allergens with highest positive reaction rates were hydroperoxides of linalool, hydroperoxides of limonene, methylisothiazolinone, nickel, and cobalt. Seven of the top 38 allergens with the highest reaction rates are not currently included in the Mayo Clinic Pediatric Patch Test Series, and 11 are not currently included in the Pediatric Baseline Series (as developed by the Pediatric Contact Dermatitis Workgroup). Conclusions: Patch testing is a useful tool to diagnose children with ACD. With new products and exposures, there is an opportunity to expand current pediatric patch testing series.
Allergic Contact Dermatitis in Patients with Hidradenitis Suppurativa: A Retrospective Analysis
McKenzie, Ning C. , Schaefer, Lauren , Killian, Jill M. , Youssef, Molly J. , Davis, Mark D.P. , McKenzie, Ning, Killian, Jill, Youssef, Molly, Alavi, Afsáneh

Mayo Clinic

Dermatitis® | January 3, 2024 | Volume: 35 | Issue: 5 | Pages: 525-527

10.1089/derm.2023.0124 | PMID 38170189 Get It

Value of dermatology hospital conference as a continuing medical education‐accredited activity: A retrospective review
Maniam, Ganesh , Isaq, Nasro , Wetter, David A. , McEvoy, Marian T., Alavi, Afsáneh , Camilleri, Michael , Davis, Mark D. P. , Sartori‐Valinotti, Julio C. , Davis, Mark D.P. , Camilleri, Michael Joseph , Alavi, A , Cantwell, Hafsa M. , el‐Azhary, Rokea A.

Mayo Clinic

JEADV Clinical Practice | December 22, 2023 | Volume: 3 | Issue: 2 | Pages: 647-652

10.1002/jvc2.351 Get It

AbstractBackgroundDermatology grand rounds are popular educational activities among dermatologists and trainees, contributing to improved knowledge and skills. Dermatology hospital conferences at Mayo Clinic Dermatology are separate from dermatology grand rounds in that they focus on inpatient consultations and dermatology admissions.ObjectivesThis study aimed to determine the types of cases presented during dermatology hospital grand rounds and evaluate the educational value of this continuing medical education (CME)‐accredited activity.MethodsThis retrospective study reviewed all inpatient dermatology cases presented during hospital grand rounds at Mayo Clinic Dermatology in Rochester, MN from 2019 to 2022; this study also reviewed the compiled surveys of faculty participants at our institution from 2019 to 2022.ResultsA total of 389 cases met the inclusion criteria for analysis. The most common diagnostic category was inflammatory/autoimmune diseases (157 cases, 40%), followed by infection or infestation (73 cases, 19%), drug‐induced eruptions (49 cases, 13%), neoplastic or metastatic diseases (41 cases, 11%), genetic/congenital disorders (21 cases, 5%), depositional/nutritional/metabolic conditions (15 cases, 4%) and wound/traumatic/iatrogenic dermatoses (12 cases, 3%), which were the least common. Most cases were presented for discussion of diagnosis and management (246 cases, 63%), but others focused on the arrival of diagnosis (119 cases, 31%) or management alone (24 cases, 6%). The compiled surveys of faculty participants (n = 50) indicated high satisfaction with dermatology hospital grand rounds, with the majority expressing that evidence‐based research was incorporated and positively impacted their practice. Most respondents indicated that hospital conference participation improved knowledge (97%), competence (64%), clinician performance (54%), patient outcomes (52%) and team performance (50%).ConclusionsThe cases presented during these conferences spanned from challenging inflammatory diseases to simple dermatoses, with over 800 literature references reviewed. Dermatology hospital grand rounds provide high value as a CME‐accredited activity for dermatology faculty, even for those without a specific interest in hospital/inpatient dermatology.